Sequencing Challenges Persist in Metastatic Prostate Cancer
In this interview, Scott Samuelson, MD, explains that there is no definitive evidence to support the use of one agent over another in subsequent lines of therapy. Samuelson also says that he encourages providers to talk with their patients about the various costs, comorbidities, and side effects of each treatment.
source: Caroline Seymour - OncLive